chongqing zhifei biological products' 23-valent pneumonia vaccine joins the "price reduction group" just one year after its launch.

① Chongqing Zhifei Biological Products 23-valent pneumococcal polysaccharide vaccine has lowered its online price by nearly 30% in provinces such as Jiangsu and Jilin; ② Currently, China's pneumococcal vaccine market is showing a competitive situation of "wrestling" between overseas MNCs and domestic companies, and more and more companies are expanding their presence in this field; ③ Industry experts believe that in order to occupy the market, companies can only choose to actively reduce prices.

cls.cnSep 4 07:55 ET

Chongqing Zhifei Biological Products Co., Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Simply Wall StAug 31 20:38 ET

Zhifei Biotech: 2024 Semi-Annual Report

SZSIAug 29 12:00 ET · Announcements

Zhifei Biotech: 2024 Semi-Annual Report Summary

SZSIAug 29 12:00 ET · Announcements

The batch issuance of the quadrivalent HPV vaccine has dramatically decreased, and chongqing zhifei biological products' revenue and net profit have both declined. Interpretation of the financial report.

Due to the decrease in sales volume of H1's main products, Chongqing Zhifei Biological Products reported a decrease in revenue and net income in its semi-annual report. The volume of Merck's quadrivalent HPV vaccine, which the company represents, decreased by more than 90% compared to the previous year. With the accelerated development of domestically-produced nine-valent HPV vaccines, the company's pressure will further increase.

cls.cnAug 29 11:32 ET

Chongqing Zhifei Biological Products (300122.SZ) releases its half-year performance with a net income of 2.234 billion yuan, down 47.55%.

Chongqing Zhifei Biological Products (300122.SZ) released its 2024 interim report, during which the company achieved revenue...

Zhitong FinanceAug 29 11:16 ET